Cat. No. | Product Name | Target | Signaling Pathways |
---|---|---|---|
T72374 | PI3K/mTOR Inhibitor-12 | PI3K | PI3K/Akt/mTOR signaling |
PI3K/mTOR Inhibitor-12为口服有效且选择性的PI3K/mTOR抑制剂,对PI3Kα和mTOR的IC50分别为0.06 nM及3.12 nM,表现出抗肿瘤活性且肝毒性较低。 | |||
T7166 |
GNE-493
|
PI3K; mTOR | PI3K/Akt/mTOR signaling |
GNE-493 是选择性的PI3K/mTOR 抑制剂,能够抑制 PI3Kα (IC50:3.4 nM),PI3Kβ (IC50:12 nM),PI3Kδ (IC50:16 nM),PI3Kγ (IC50:16 nM) 和 mTOR (IC50:32 nM)。 | |||
T63470 |
PI3K/mTOR Inhibitor-8
|
||
PI3K/mTOR Inhibitor-8 是 PI3K (PI3Kα IC50: 0.46 nM) 和 mTOR (mTOR IC50: 12 nM) 双重抑制剂。PI3K/mTOR Inhibitor-8 能够将 HCT-116 细胞的细胞周期阻滞在G1/S 期,并诱导其凋亡 (apoptosis)。 | |||
T61516 |
PI3K/mTOR Inhibitor-3
|
||
PI3K/mTOR Inhibitor-3 (compound 12) is an imidazoline compound with potent dual inhibitory effects on PI3K and mTOR. This compound exhibits notable anti-cancer activity [1]. | |||
T68485 |
Apilimod HCl
|
||
Apilimod dimesylate is a potent and selective PIKfyve inhibitor. It exhibits no significant activity at other lipid kinases and protein kinases, including PIP4K, PIP5K, mTOR, PI3K and PI4K. Apilimod dimesylate inhibits cellular entry by SARS-CoV-2, MERS-CoV and MHV S pseudovirions. It reduces the number of SARS-CoV-2-infected hiPSC-derived pneumocyte-like cells by 85% and inhibits SARS-CoV-2 replication in donor lung tissue. It also exhibits selective cytotoxicity in B-cell non-Hodgkin lymphoma ... |